GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Constellation Pharmaceuticals Inc (NAS:CNST) » Definitions » EPS without NRI

Constellation Pharmaceuticals (Constellation Pharmaceuticals) EPS without NRI : $-3.04 (TTM As of Mar. 2021)


View and export this data going back to 2018. Start your Free Trial

What is Constellation Pharmaceuticals EPS without NRI?

Constellation Pharmaceuticals's earnings per share without non-recurring items for the three months ended in Mar. 2021 was $-0.84. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2021 was $-3.04.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Constellation Pharmaceuticals's EPS without NRI or its related term are showing as below:

CNST' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 6.2   Med: 32.8   Max: 59.4
Current: 6.2

CNST's 3-Year EPS without NRI Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 4.7 vs CNST: 6.20

Constellation Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2021 was $-0.84. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2021 was $-3.04.

Constellation Pharmaceuticals's EPS (Basic) for the three months ended in Mar. 2021 was $-0.84. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2021 was $-3.04.


Constellation Pharmaceuticals EPS without NRI Historical Data

The historical data trend for Constellation Pharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Constellation Pharmaceuticals EPS without NRI Chart

Constellation Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20
EPS without NRI
-45.52 -3.40 -5.00 -3.04 -2.81

Constellation Pharmaceuticals Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.61 -0.70 -0.71 -0.79 -0.84

Competitive Comparison of Constellation Pharmaceuticals's EPS without NRI

For the Biotechnology subindustry, Constellation Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Constellation Pharmaceuticals's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Constellation Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Constellation Pharmaceuticals's PE Ratio without NRI falls into.



Constellation Pharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Constellation Pharmaceuticals  (NAS:CNST) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Constellation Pharmaceuticals EPS without NRI Related Terms

Thank you for viewing the detailed overview of Constellation Pharmaceuticals's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Constellation Pharmaceuticals (Constellation Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
215 First Street, Suite 200, Cambridge, MA, USA, 02142
Constellation Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead products include CPI-0610, which is a small molecule designed to promote anti-tumor activity by specifically inhibiting the function of BET proteins, which normally enhance target gene expression, and CPI-1205 which is a small molecule designed to promote anti-tumor activity by specifically inhibiting EZH2, an enzyme that suppresses target gene expression. It operates in the segment of the development of novel therapeutics in the field of epigenetics.
Executives
Emma Reeve officer: Chief Financial Officer C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Column Group L P 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Karen Valentine officer: See Remarks C/O ANTIGENICS INC., 3 FORBES RD, LEXINGTON MA 02421
Mark A Goldsmith director, 10 percent owner 925 PAGE MILL ROAD, PALO ALTO CA 94304
Jeffrey Humphrey officer: Chief Medical Officer C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200, CAMBRIDGE MA 02142
Steven L. Hoerter director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Elizabeth Trehu director C/O JOUNCE THERAPEUTICS, INC., 1030 MASSACHUSETTS AVENUE, CAMBRIDGE MA 02138
Scott Braunstein director C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
James E Audia director 215 FIRST STREET, SUITE 200 CAMBRIDGE MA 02142
Adrian Senderowicz officer: Chief Medical Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Jigar Raythatha director, officer: See Remarks C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Patrick Trojer officer: Chief Scientific Officer 215 FIRST STREET SUITE 200 CAMBRIDGE MA 02142
Richard S Levy director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Ponoi Management, Llc 10 percent owner, other: General Partner 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
David V Goeddel 10 percent owner, other: Managing Partner C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158

Constellation Pharmaceuticals (Constellation Pharmaceuticals) Headlines

From GuruFocus